Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That's right. And it's just very thin. I know from what I'm holding and a handful of others that the float is pretty well soaked up. No one wants to sell, and it's getting much harder to accumulate a decent position without simple slapping the ask and taking what you want before further movement.
I should know, I've added millions of shares at higher and higher prices over the past weeks, simply because I didn't buy enough when they were dangled out there at lower prices. Bought a lot yesterday and more today. ASCM has been doing a good job of making the market today, but never gives up much before moving to higher prices.
RXMD Yes, that's right! Brilliant point made there, INSTA!
I think a lot of folks are going to begin realizing very soon just how much of an entrepreneur and visionary Armen really is. He's had to do a lot of the hard slogging work that comes with a public company - more than Musk, obviously, because Progressive Care couldn't possibly have the resources Musk employed with his PayPal profits and silicon valley network, etc. - but he has shown that he is very much a forward-thinking entrepreneur with a real vision in the world of health care from the pharmaceutical treatment perspective. And it's (his vision and entrepreneurship) really going to begin shining much more brightly with every month forward, now.
I've just been very happy for years that I found RXMD at the time that I did back in 2015. So has my wallet, lol.
RXMD That's right, very true statement. But for all intents and purposes, they both effectively started the businesses that turned into what they are today. Tesla never would have been what it has become if Musk didn't turn it into something different that it was. Same for Armen and Progressive Care. I think this truth character has given up on his soft bash topic for now.
Ummm, I don't get the sense in your comment here. Armen STARTED Progressive Care, he is THE biggest factor in DEVELOPING the business, and he's obviously GROWING the existing business... in a BIG way.
"...for free"?? Lol, Armen pretty much BUILT this company - and therefore the opportunity for you and me to profit from it while sitting on our tushes and spilling our opinions at will.
Why don't you check with the Tesla shareholders and ask about the 10s of BILLIONS of dollars in stock that Elon Musk has been "given" for free. I've made money on Tesla stock, and I love Tesla products. I have NO COMPLAINTS about "free shares" given to Musk. And I have no complaints about "free shares" given to Armen.
I think some folks hear "negative talking points" as they bounce around in an echo chamber like this one, and they actually start establishing a belief system around these anonymous "opinions." To those folks, I just say... THINK. For yourself, first. But THINK about your own role, and then about how that opportunity comes about, and who is crucial in driving value into your stock. And what that's worth for you to make "easy money" in your recliner.
Again?!? They have NEVER "diluted the hell out of!"
I was there in 2014-2015 with many of the longs through the massive clean-sheet debt paydown that "diluted" in order to accomplish that goal. It was actually a very good thing for the company and for long shareholders, and the business strength and growth has been much better as a result. Since THAT time - it has been over 5 years now - they have still not even doubled the O/S, though the business has grown immensely since then.
This will soon be reflected in the stock price, and will only trend strongly positive from there due to the parts recently and currently being put in place for massive future growth.
$RXMD Done! Another cog in this huge growth machine noted in today's news! Highest growth segment of the business leveraged and bolstered. I love seeing these things from management.
RXMD 1,014 watchers on Stocktwits at this moment. Also, RXMD moved up from #12 (~11pm) to #8 (now) on the Most Read Boards here.
Interest continues to grow, and at a rapid rate.
Yeah, that's alright. The Reddit folks can come here and be pointed to the facts and sources, right? Or even better, maybe some will actually do their own DD...
https://www.otcmarkets.com/stock/RXMD/overview
https://www.progressivecareus.com/
Also, the statement (at bottom) about not being current with SEC filings is not accurate. Just FYI - that is incorrect.
$RXMD Just remember that "fair value" in today's market is much higher than most will think, until it's too late and they've given too much of their so-called long position to others who take the price 2x, 3x, or even 10x higher.
Speaking from experience here. I've held some of these stocks lately and done very well. Others I have sold way, way too soon because I had no clue the market would move so high and so fast. RXMD is a VERY solid company with high revs, proven strong growth performance, and VERY substantial growth potential. And if that's not enough, the setup for much higher pps growth catalysts is simply perfect!
I don't usually talk very specific about price targets, but this is one stock that I will still be holding a very strong position at over $1. I have seen - and have held (and still holding decent positions) - more than one penny stock recently to over $1 and as high as $9, just within the past several weeks. RXMD is one of the strongest companies trading on OTC, let's see what happens here!
$RXMD Thanks for posting the investor deck, Wackamole. Love seeing this and can't see it enough. Having invested in RXMD since August 2015, I know there are many here (and lurking) who've put their money behind Progressive Care management starting years before that!
Great business, excellent proven performing management, an incredible business model with established footholds in several near-term high-growth business segments with sky's-the-limit headroom for revenue gains - AND with new and disruptive technology for new AND established markets!
RXMD is an unbelievable virtually-NO-risk high growth investment opportunity for any and all getting on board this year even, as the stock has been percolating for several years, and is only now getting ready to blow the top.
With historic, new AND ongoing business expansion, and with M&A actions over the past few years, improved AUDITED reporting and "recent" OTCQB listing, AND the current plans for uplisting - RXMD is unarguably one of THE BEST companies/stocks for investors to park a decent chunk of profits from tapped or liquidated positions, and... just sit back, buy on dips as higher lows are established, and enjoy the ride for years forward.
A suggestion for investors: Use this stock - and whatever stock of a possible future buyer of Progressive Care that it may convert to down the road - to compound recent gains in your investment accounts to become the generational wealth building and transfer vehicle that many of us have always known it could and would be.
For example, I have officially reclassified RXMD as a "big board" long-term buy/hold stock and am building larger positions in all of my accounts (and with a "mental" emphasis on the IRAs, though I treat all of the accounts the same).
It's a good idea, but I think it's too small a case with too many questions that would have to be answered for there to be enough proof of the thing (e.g. exactly where was NITE on the ASK, which MM was low ASK with the 30k shares, what was NITE trading pattern that day/afternoon, what did NITE have to gain (motive/motivation), etc.) before there would be any interest from the SEC to dig further. I think more hassle than I want to deal with, considering that I already spent this time to share a fact case with other retail traders so folks can be a little more informed. I think this latter part was the most value in this case.
$JUSHF Fair market value is currently US$19.49, reports Simply Wall St. Compare this valuation to the current price of US$7.46 per share) - Based on the analysis by Simply Wall St., JUSHF is currently undervalued by 61.7%.
https://simplywall.st/stocks/us/pharmaceuticals-biotech/otc-jush.f/jushi-holdings#intrinsic-value
As Jushi continues to grow rapidly, the value is only going to increase just as rapidly - or more likely, at an increasing rate due to power factor in comparison to slower growing peers.
I think we could very possibly see a $40+ price tag within the next year.
I'm really looking forward to 5x+ growth of a hefty and growing position in JUSHF over the next year or so!!! As I always say and always do... buy the dips!!
$JUSHF Published just yesterday morning (Saturday, Feb 20), Motley Fool lays out the basis for 2x to 3x JUSHF stock price improvement just to get to fair market value RIGHT NOW.
https://www.fool.com/investing/2021/02/20/3-unstoppable-small-cap-stocks-to-buy-right-now/
Where the author notes that "Most pot stocks are valued at anywhere from four to five times Wall Street's forecasted sales for 2022 or 2023," he reports that Jushi's market cap is only 2.4x projected 2022 sales and 1.6 times 2024 sales. This translates to the current share price being only around 1/3 to 1/2 of current market value.
Motley Fool is NOT the only source to report this undervaluation.
The article (excerpt):
3 Unstoppable Small-Cap Stocks to Buy Right Now
Game-changing returns are just a click of the buy button away.
Sean Williams
Feb 20, 2021 at 6:06AM
This could turn out to be a very big year for the relatively young bull market. The Federal Reserve has pledged to keep lending rates at or near historic lows through 2023, and the Biden administration is fine-tuning a plan to spend as much as $1.9 trillion on a new fiscal stimulus package. This would come atop the more than $3 trillion spent last year in response to the coronavirus disease 2019 (COVID-19) pandemic.
With access to cheap capital readily available, businesses of all sizes should benefit. However, it might be especially good news for small-cap stocks.
Following the March 2020 bottom, we've watched established and/or high-growth large-cap businesses thrive. Meanwhile, small-cap stocks (publicly traded companies with a market cap ranging from $300 million to $2 billion) have mostly lagged. But with so much available capital and investors' appetite for risk returning, this trend may be ready to reverse.
If you're looking to add unstoppable small-cap stocks to your portfolio, the following trio can be bought with confidence right now.
1. Jushi Holdings
Despite the incredible volatility we've witnessed in North American marijuana stocks since 2017, cannabis is an industry with incredible growth prospects this decade. That's why small-cap multistate operator Jushi Holdings (OTC:JUSHF) is such an unstoppable force in the largest marijuana market in the world, the United States.
Though Jushi has retail or cultivation operations in around a half-dozen legalized states (36 U.S. states have waved the green flag on weed in some capacity), it's the company's core focus on three states that makes it unique.
In 2021, Pennsylvania, Virginia, and Illinois are expected to account for around 80% (or more) of total sales for Jushi. What these states have in common is that they issue cannabis-dispensary licenses on a limited basis. In Pennsylvania and Illinois, only a preset number of licenses can be granted. Meanwhile, in Virginia, licenses are issued on a jurisdictional basis.
The point is, Jushi is focusing its efforts on states where competition will be limited or nonexistent, which should allow it to build up its brand and gobble up lucrative market share. You know the phrase, "work smarter, not harder?" This is it in action.
Even after a roughly tenfold increase in its shares since the March 2020 bear market bottom, Jushi remains relatively inexpensive. Most pot stocks are valued at anywhere from four to five times Wall Street's forecasted sales for 2022 or 2023.
As for Jushi, its $902 million market cap is approximately 2.4 times projected 2022 sales and 1.6 times 2024 sales, based on Wall Street's consensus. Plus, with adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) guidance of $40 million to $50 million in 2021, there's a really good chance the company will turn the corner to recurring profitability this year.
If you need one more reason to like Jushi, let it be this: Management and insiders collectively put up $45 million of the first $250 million in capital raised by the company. When the interests of management and shareholders align, investors tend to do very well.
$JUSHF Here's an excellent review of Jushi!
Just published last week, Feb 17. If you don't know enough about Jushi, this gives a great overview. There's SO much more that can be shown to convey the strength, growth trajectory and profit potential of this business - management, financials, products, markets, etc. - but this 15 minutes would be the best 15 minutes spent by a prospective new investor.
https://stocktwits.com/The_Next_Multibagger/message/290858341
$JUSHI Jushi Holdings ("Buy" PT raised to C$12.50) is a cheap pot stock, Beacon Securities says.
https://www.cantechletter.com/2021/02/jushi-holdings-is-a-cheap-pot-stock-beacon-securities-says/
By Nick Waddell February 16, 2021
Jushi Holdings is a cheap pot stock, Beacon Securities says
With legalization coming to the state of Virginia, cannabis company Jushi Holdings (Jushi Holdings Stock Quote, Chart, News, Analysts, Financials CSE:JUSH) should be a major benefactor, according to analyst Russell Stanley of Beacon Securities. In an update to clients Friday, Stanley reiterated his “Buy” rating for JUSH and raised his target price from C$9.50 to C$12.50, representing at press time a projected 12-month return of 25 per cent.
Virginia took a big step forward in the push to legalize adult-use marijuana when earlier this month both of the state’s General Assembly chambers voted in favour of recreational usage. The House of Delegates passed a bill to eliminate criminal penalties for marijuana possession while Virginia’s Senate passed a bill to establish a regulatory framework including taxation on retail sales.
With a population of 8.5 million, Virginia has had a number of marijuana-related developments along the way, with limited medical use legalized in 2015, followed by broadened medical use in 2018, an expansion in terms of product forms of THC and CBD to allowable forms such as oils, capsules and patches and the decriminalization of possession of up to one ounce.
While adult-use stores aren’t expected to open until 2024, the newly passed legislation would include a provision to legalize the sale of cannabis flower for medical use, with that development potentially being enacted as early as this year. Passing the rec cannabis bill would make Virginia the 16th state in the union to do so, just the third to legalize adult-use through legislative process and the first state in the South to have legal rec sales.
In his report, Stanley said the developments in Virginia should be good for Jushi, a multistate operator focusing on limited license markets and with interests in Illinois, Pennsylvania, Virginia, California, Nevada and Ohio.
“While work is required before the legislative session ends February 27th, the progress to date is impressive,” Stanley wrote. “We believe the flower progress was largely overlooked, given the media focus on adult-use. Flower often represents ~50 per cent of sales in markets that allow it, so legalization for medical use could double the addressable market for JUSH, ceteris paribus.”
“We also expect the flower bill to be enacted far sooner (likely 2021 versus 2023/2024 for adult-use),” Stanley said. “JUSH is one of just four companies licensed to operate in VA, with each licensee allowed to open six dispensaries within their assigned health service area (HSA). JUSH is the only company currently allowed to open dispensaries in HSA II, the region just outside of Washington DC and home to 2.5 million people.”
Last week, Jushi announced the close of its overnight marketed offering of 7.475 million shares including over-allotment for net proceeds of about $56 million. The company aims to use the funds for repaying senior secured notes, acquisitions, general corporate purposes and strategic transactions, potentially including the purchase of its 93,000 sq ft facility in Prince William County, Virginia, currently operated by Jushi’s wholly-owned subsidiary. (All figures in US dollars except where noted otherwise.)
“Subject to regulatory approvals, the acquisition, together with the planned build-out of the facility, will enable the Company to efficiently produce a consistent supply of medical products as patient access improves and as the medical program matures and expands,” Jushi said in a February 12 press release.
Stanley is estimating JUSH to have over $100 million in dry powder to fund potential strategic transactions. In terms of a forecast, the analyst has raised his 2022 revenue and EBITDA estimates on the Virginia news, while he has also increased his valuation multiple from 13x to 14x 2022 EBITDA.
Now, Stanley is calling for 2021 revenue and adjusted EBITDA of $223 million and $45 million, respectively, and 2022 revenue and adjusted EBITDA of $465 million and $176 million, respectively.
Stanley is estimating JUSH to be trading at a 40 per cent discount to the 19x 2022 EBITDA average among its US operator peer group and at a 45-per-cent discount to the 21x average among the broader peer group.
“Potential near-term catalysts include M&A activity, progress on the retail and cultivation build-outs in Pennsylvania (population 12.8 million), the Q4/20 results, and further regulatory progress in Virginia,” Stanley said.
Jushi last reported quarterly earnings in late November where its third quarter 2020 featured revenue up 67 per cent sequentially to $24.9 million and adjusted EBITDA of $1.9 million compared to a loss of $1.2 million for the previous quarter. Gross profit grew 64 per cent sequentially to $12.3 million.
The company updated on January 4, 2021, its fourth quarter 2020 guidance, now calling for Q4 revenue of between $32 and $33 million (up from $28-$30 million) with a maintained adjusted EBITDA guidance of $2.5-$3.0 million.
$JUSHF Jushi is poised to springboard from this dip. Hope everyone got their fills down here, because we're not going to linger for long.
Okay, here's the link. If you read the entire story, I think you'll find it VERY interesting, especially when you get to the tail end.
https://worldnewsera.com/news/us-news/high-speed-trading-firm-linked-to-robinhood-is-going-to-war-with-the-sec/
Don't be fooled by the title in this link. The story actually starts out and clarifies what I described about this new proposed algorithm (that the SEC did in fact approve, and it is effective now since October 1!), and THEN it ties together two more interesting components of recent news/events.
There are 3 significant components of this story that relate to my post, as well as the big issues we're all seeing in the market in recent weeks.
Also, it turns out that it's IEX - a NASD-competing exchange - that made the new algorithm proposal to the SEC.
ALSO also, the rule went into effect in October. It's conceivable that Knight implemented this very feature into their algorithm to accomplish exactly what happened to my order on Friday!
Especially, note the last subject matter discussing how Citadel was sued by the SEC and got away with a little hand slap ($700K fine) for 1) delaying order execution (sound familiar? my order sat for over a minute and still didn't completely fill), and 2) getting IN FRONT of retail orders to take shares (also sound familiar?). Aaaannndd... Citadel pays a little fine and goes on about their manipulation business, as we all know too well.
The article text:
-----------------------------------------
High-speed trading firm linked to Robinhood is going to war with the SEC
Evelyn Blackwell2 weeks ago 4 minutes read
High-speed trading firm linked to Robinhood is going to war with the SEC
The timing of Citadel’s 77-page court filing Tuesday was unrelated to the recent market turbulence. Citadel Securities filed its intention to sue in October and the two sides agreed last fall to a February 2 deadline for a brief.
Known as D-Limit, IEX says the order type is designed to help protect investors from predatory trading strategies. Short for discretionary limit, IEX says D-Limit acts like a regular limit order except when the exchange’s algorithms predict a price is about to change. A limit order is an order to buy or sell a stock at a determined price or better.
However, Citadel Securities is arguing D-Limit does the opposite of protecting investors. In 77 pages of court documents filed Tuesday, Citadel Securities accused the SEC of having “ignored” evidence that retail investors would be “harmed” by the D-Limit order. The firm cited its own analysis that found more than half of its trading activity on IEX was on behalf of retail investors, not for its own profit.
Citadel Securities, a major source of revenue for Robinhood is owned by billionaire Ken Griffin.
To make its case about how retail investors can be harmed by D-Limit, Citadel Securities compared it to shopping at a store.
“Imagine a grocery store that has deliberately installed extra-long conveyor belts on its checkout lines,” the company argues in the filing. In theory, the store could use that extra time to determine if any items have sold out at rivals’ stores.
“If so, the store’s computers quickly raise its own price before your item reaches the cashier,” the filing says.
The SEC did not respond to a request for comment. IEX said it looks forward to responding to the Citadel Securities filing and pointed to public trading data that it says shows D-Limit delivers better trading results and pricing to investors.
‘Predatory’ trading strategies
The claims by Citadel Securities come despite the fact that last year Republicans and Democrats at the SEC unanimously approved the rule, which was also backed by large pension funds and asset managers like T. Rowe Price.
D-Limit was even blessed by Better Markets, the tough-on-Wall-Street nonprofit run by Dennis Kelleher, who was on President Joe Biden’s transition agency review team.
IEX’s D-Limit, along with the exchange’s other technology, can “protect investors against predatory” trading strategies, Lev Bagramian, senior securities policy advisor at Better Markets, told CNN Business in an email.
Kelleher said D-Limit would shield investors specifically from Citadel Securities — and by extension hurt the firm’s booming revenue.
“Presumably that’s why Citadel vehemently opposed IEX’s D-Limit order type,” Kelleher said.
Wall Street is keeping very close tabs on WallStreetBets. Here's how
IEX was founded in March 2012 by former Wall Street executive Brad Katsuyama, a central character in Flash Boys, which made the case that high-speed traders are preying on mom-and-pop investors. IEX was approved as an exchange in August 2016.
“Despite the current environment,” Katsuyama told CNN Business in a statement, “Citadel has followed through on their attempt to reverse the SEC’s approval of an innovation that is designed to protect all investors from predatory trading strategies.”
A Citadel Securities spokesperson pointed to an October statement in which the firm said the SEC “failed to properly consider the costs and burdens imposed by this proposal that will undermine the reliability of our markets and harm tens of millions of retail investors.”
Although D-Limit won unanimous support from the SEC, some companies warned the agency in comment letters not to approve the rule.
Nasdaq, a rival exchange to IEX, slammed D-Limit as “nothing more than a thinly veiled attempt by IEX to bolster its dismal market quality for displayed orders.”
Elizabeth Warren raises questions about Robinhood, Citadel
The lawsuit comes as scrutiny intensifies on Citadel Securities in the wake of the Reddit-driven market volatility and Robinhood’s controversial decision to temporarily suspend purchases of GameStop (GME), AMC (AMC) and other stocks backed by WallStreetBets.
Treasury Secretary Janet Yellen summoned federal regulators to look into the market turbulence this week and lawmakers have called for an investigation.
Robinhood, which championed the free-trading business model that is now common in the industry, has repeatedly said that its trading restrictions on GameStop were driven by soaring financial requirements during the market volatility, not at the behest of Wall Street firms hurt by the GameStop rally.
But Warren, a Democrat from Massachusetts, said Robinhood’s trading limits on small investors “raises troubling concerns about its relationship with large financial institutions that execute its trades.”
Specifically, Warren pointed to Robinhood’s ties to Citadel Securities.
‘You’re the product’
Like other brokerages, Robinhood gets paid to route orders to market makers, a controversial practice known as payment for orderflow. In December alone, Robinhood generated about $12.4 million by routing orders to Citadel Securities, according to disclosure forms.
Critics say it is only free to trade on Robinhood because the app sends orders to market makers, enabling them to trade ahead of those retail flows.
Inside the Reddit army that's crushing Wall Street
“With anything that’s free, you’re the product,” Mark Yusko, CEO of hedge fund Morgan Creek Capital Management, told CNN Business earlier this week.
Another entity owned by Griffin, the hedge fund Citadel, provided a $2 billion bailout to GameStop short-seller Melvin Capital Management after its bets blew up.
Both Citadel Securities and Citadel the hedge fund denied any role in Robinhood’s decision to stop purchases of GameStop.
In a statement, Citadel Securities said it has not “instructed or otherwise caused any brokerage firm to stop, suspend or limit trading or otherwise refuse to do business.”
The SEC clash isn’t the only time Citadel has been in the headlines recently with a regulator. Last year FINRA, Wall Street’s self-regulator, fined Citadel Securities $700,000 for trading ahead of customer orders. FINRA said that over a two-year period Citadel Securities delayed certain equity orders from clients — while continuing to trade those same stocks in its own account. Without admitting or denying the findings, Citadel accepted and consented to the FINRA action.
There you go, I agree. That is #1 on the list of likely explanations. However, Knight has been known to step over the line, just like Citadel, so I don't give them much credit for simply having "...sold more than they bought" - I would add that it's intentional.
These MM's make money on their "market making," and they are given a lot of latitude by the SEC. They employ certain algorithms to execute trades, and they do a lot of tricky things with these algos. They go as far as they can go without a) getting caught, or b) exceeding such a level that it's worth it to the SEC to i) investigate, and ii) prosecute, or c) doing it so predictably that they can be easily caught, or any number of other lines they may draw to limit culpability or liability with their manipulations. They've been sued by the SEC many times, they've settled cases by paying fines, but they still continue with their manipulations.
I forget what the most recent proposal was that I came across from one of the major dealer-brokers, but the proposal was to the SEC, and they wanted to be allowed to effectively "spoof" buy/sell orders by creating/using an algorithm that would yank orders before they get executed if/when it suits them... saying that it would help make the markets function more smoothly. REALLY?!? What a crock! That's called SPOOFING!
Here, for years retail traders are chastised (if not outright threatened) by dealer-brokers if/when they spoof trade orders, threatening that it's illegal and constitutes stock manipuation and could result in stiff penalties including substantial fines and imprisonment, and now they propose that the SEC allow THEM to do such manipulation - to THEIR advantage (for making money, probably in combination with their currently existing SEC-authorized "market-making" algorithms).
No wonder some number of retail traders wanted to band together against wall street. Now they just need to find a way to put it to the naked-stock-shorting MMs, now that they made an example of a few micro-stock-shorting hedge funds.
Well, there's no doubt about the MM/broker-dealer manipulation.
I put in an order for 100,000 shrs just over 1 minute before the close (3:58:57pm EST). So, it took over 1 minute to get just 63,578 shares filled - leaving 36,422 that never filled. Instead of giving me the 30,330 shrs that were sitting on the ASK at .111, I got "air shares," and then after the last-second .105 trade, they printed the T-trade for 30,330 shrs which also did NOT go to me. Yeah, no doubt about the manipulation here.
I wasn't planning to wait until the last minute to buy more shares in the afternoon, but was on an important phone call and didn't realize the time. I just happened to glance at the clock in time to get an order in... and there's no reason for not getting filled with that order (below).
Looks to me like a clear example of the sh*t that Knight (MM:NITE) has been in trouble for time and again. I hope they have a full-autonomous manipulation algo playing that gets squeezed on news. I know a few thou or 10s (even 100s) of thou won't hurt them, but it still feels good to see occasionally, lol. But I'm still loading, so I won't mind too much if I can pick up some more in this range.
As I write this, looks like we're ratcheting up again to underline the hold strength of the recent 50,000+ move/level.
$GBTC You are correct, Ann1, the premium has narrowed over the past couple of months. You can track it if you want (see image below), FooBar has been giving updates on it, and you can also get the info from Grayscale's daily Twitter updates. But... it really has no impact unless you're day-trading GBTC. Even then... if you're using GBTC for direct Bitcoin exposure in an equity trading plan (e.g. buy/sell Bitcoin or use as a cash sweep account in combination with other equity trades for rapid compounding of gains), it makes no sense at all to let the changing spread affect your buy/sell swings. Just love it and use it. Been working great for me!
$JUSHF I hope everyone is taking advantage of the dip - 20% of the float has now traded at 7.5 and higher. It's a pretty easy call imo, don't try to flip, just add on the dip... and you'll be a very happy camper by fall!
RXMD Hey Insta, good to see you back! The volume is starting to ramp up - with a little more, you might get that wake up call soon!!
$RXMD I think I've mentioned before, I do believe this about Oleg Firer as CEO has always - since you originally brought this up - made the most sense to me.
Picked up another nice chunk here today. I'd say that I've just been sitting back and enjoying the ride here, but I can't help adding just about every day, definitely every week before RXMD really takes off! Lotsa nice gains from other positions to pile on, fortunately.
$RXMD Thanks for posting the investor deck, Wackamole. Love seeing this and can't see it enough. Having invested in RXMD since August 2015, I know there are many here (and lurking) who've put their money behind Progressive Care management starting years before that!
Great business, excellent proven performing management, an incredible business model with established footholds in several near-term high-growth business segments with sky's-the-limit headroom for revenue gains - AND with new and disruptive technology for new AND established markets!
RXMD is an unbelievable virtually-NO-risk high growth investment opportunity for any and all getting on board this year even, as the stock has been percolating for several years, and is only now getting ready to blow the top.
With historic, new AND ongoing business expansion, and with M&A actions over the past few years, improved AUDITED reporting and "recent" OTCQB listing, AND the current plans for uplisting - RXMD is unarguably one of THE BEST companies/stocks for investors to park a decent chunk of profits from tapped or liquidated positions, and... just sit back, buy on dips as higher lows are established, and enjoy the ride for years forward.
A suggestion for investors: Use this stock - and whatever stock of a possible future buyer of Progressive Care that it may convert to down the road - to compound recent gains in your investment accounts to become the generational wealth building and transfer vehicle that many of us have always known it could and would be.
For example, I have officially reclassified RXMD as a "big board" long-term buy/hold stock and am building larger positions in all of my accounts (and with a "mental" emphasis on the IRAs, though I treat all of the accounts the same).
$ALPP That's right, Chaka - proud and very happy to be invested in a company from a penny to NASD, and to do this without a RS is an amazing accomplishment! Getting ready to toast Alpine 4 & Co and all ALPP investors AGAIN!!
$GBTC She's gonna bloooowwwwww! 50,000 will be behind us very soon!
$RXMD Nice piece of news today! And you pretty much nailed it - Volume: 9,735,004 and high of .0839, close .081
Management is doing all the right things and more, and the public is starting to know it. Gotta luv being in at the bottom with a monster growth machine!
I think this was a MM setup for a large buy that's coming. I've seen many large buys in JUSHF over the past months, and... just take a look at the chart. Yesterday's touch of 7 was a setup for today's low-volume walkdown that probably did trigger a stop loss or two (more?). Watch a buy order come through today or tomorrow for $2-$3M or more. Likely will see a handful of those orders over a few days or a week. We're going to double digits within days, imo.
$JUSHF YUMMMMM! Thank you, that was a delicious dip! :)
Well, not bad at all, got the 4.20s and much more!! GLTY Fullpower7, make some money!
I think so! Whatever just happened, I'm pissed that I didn't get filled. I've got some larger buy orders in at $4.20, lol! Okay, they're still trying to push down, maybe I'll still get them.
But yeah, I've already got a pretty large position and in several accounts, so I'm just looking for more gravy. I think there's pretty good upside still, and much potential for outsized gains from this price range given the momentum here.
$SNDL So cool that this is going to open pre-market at $4.20! 2 minutes to go.
$SNDL A mean 420 machine! 420... dollars?!? NSN YOLO (never say never) BUY! and HODL! HODL! HODL!
I don't think I can believe that, exactly. But trading is kinda weird with JUSHF on CSE (Canada), so maybe in some way what you describe could take place. But I tend to think this is either some kind of MM manipulation or an artifact of short covering (how? I dunno exactly how that might explain the price).
The first thing is, it's a relatively small number of shares to be "sweeping" down from 7.8x to 7.0 with nothing to catch them.
Second, I was there to catch some of them, for sure - 5,000 shares at 7.81 (see image below). But I didn't get 1 share and I had an order sitting there until it expired EOD. If you take a look at the attached image, you'll see my order that was placed earlier in the morning. I normally keep several orders laddered down to catch shares if/when the price dips. This just happens to be the lowest order I had active today. My other orders triggered off as the price dipped during normal trading prior to this spike in the chart. However this one never filled. So how can the MMs "sweep" through my bid like that? I wasn't able to sit there and watch, and so I didn't get to see that trade print on the tape (or multiple trades for that spike, whatever the case may be), however it may have appeared.
$SNDL You must have missed this, I'm thinking... "Upon closing of the offering, Sundial will have fully utilized the capacity under its shelf registration statement filed with the Securities and Exchange Commission (the "SEC") on Form F-3 and declared effective on January 25, 2021."
But I'm guessing you know what that means. I call it "Buy, Buy, Buy!"